Improving Dosing for Long-Acting HIV Treatment and Prevention
A platform for monitoring the efficacy and optimal dosing of long-acting ART
['FUNDING_R01'] · UNIVERSITY OF COLORADO DENVER · NIH-11121804
This project aims to find the best way to give long-acting HIV medications so they work most effectively for each person.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-11121804 on ClinicalTrials.gov |
What this research studies
Long-acting HIV medications are a new way to treat and prevent HIV, but everyone currently receives the same dose. We know from earlier studies that the amount of medication in a person's body can vary a lot, and this can affect how well the treatment works. This project wants to create new ways for people to check their medication levels at home or at a clinic. This will help doctors understand if the current dosing is right for you and if it could be adjusted for better results. The goal is to make these important medications work even better for individuals.
Who could benefit from this research
Good fit: Patients currently receiving or considering long-acting antiretroviral therapy for HIV treatment or prevention would be ideal candidates.
Not a fit: Patients not using or planning to use long-acting injectable HIV medications would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to personalized dosing for long-acting HIV medications, making them more effective and potentially allowing for longer intervals between doses for some patients.
How similar studies have performed: While long-acting ART has shown success in controlled trials, this project explores a novel approach to personalize dosing in real-world settings.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ANDERSON, PETER L. — UNIVERSITY OF COLORADO DENVER
- Study coordinator: ANDERSON, PETER L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus